Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra for hyperinflammation in COVID-19
NCT04423042Phase 3Unknown
- Sponsor
- University of Calgary
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 3 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by University of Calgary. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04423042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423042.